Non-small cell lung cancer
Not yet recruitingStudy of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery
Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+2
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Taiho Oncology Inc.








